EyePoint Pharmaceuticals (EYPT) reported six-month results from a phase 2 trial of Duravyu to treat diabetic macular edema that met primary and secondary endpoints, but its shares still slumped in premarket trading.
The company said the trial demonstrated "clinically meaningful outcomes," such as continued safety with no Duravyu-related ocular or systemic serious adverse events, and an early and sustained improvement in vision and anatomical control.
EyePoint shares were 23% lower in premarket trading
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。